Mushrooms & IBD
2023 — first IBD tissue study
The first study to test Lion's Mane on actual IBD patient biopsy specimens found it reduced key inflammatory proteins and increased the gut's primary anti-inflammatory signal.
Gravina et al., Front Immunol, 2023
8 studies
reviewed across gastroprotection, colitis, and gut microbiota
3 mechanisms
NF-κB inhibition, microbiota modulation, SCFA-GPR41/43 signaling
No human RCT
no randomized controlled trial has tested Lion's Mane in IBD patients
Gravina et al., Front Immunol, 2023
View as image ↗In 2023, a team of Italian gastroenterologists published the most clinically relevant evidence yet for Lion's Mane in inflammatory bowel disease: they took biopsy specimens from people with active IBD and applied a Lion's Mane-containing formula directly to the inflamed tissue in a lab dish. The inflamed tissue produced lower levels of two proteins that drive gut inflammation and higher levels of the gut's primary anti-inflammatory signal. That study, by Gravina and colleagues in Frontiers in Immunology, has not been cited in a single consumer-facing health article since its publication.
Lion's Mane for IBD is a topic that generates confident claims from supplement marketers and genuine caution from gastroenterologists. Both reactions are partly right. The research base is real: multiple animal studies across three distinct mechanisms, and that 2023 human tissue finding. But Lion's Mane has never been tested in a human IBD clinical trial. Knowing what that gap means, and what the existing evidence does and does not tell us, is what this article covers. For a broader guide to how mushroom polysaccharides interact with gut bacteria, see Mushrooms as Prebiotics: How They Feed Your Gut Bacteria.
Key Takeaways
- No randomized controlled trial has ever tested Lion's Mane (Hericium erinaceus) in people with Crohn's disease or ulcerative colitis
- Gravina et al. 2023 applied a Lion's Mane-containing combination to biopsy tissue from actual IBD patients and found reduced COX-2 and TNF-α (inflammatory drivers) and increased IL-10 (anti-inflammatory signal) in the inflamed mucosa
- Qin et al. 2016 found that Lion's Mane ethanol extract at 250-500 mg/kg reduced colitis severity in mice by inhibiting NF-κB and suppressing TNF-α, IL-1β, and IL-6
- Ren et al. 2018 found Lion's Mane polysaccharide simultaneously inhibited three signaling pathways (NF-κB, MAPK, Akt), reduced oxidative stress markers, and improved gut microbiota composition in a single colitis mouse study
- Pan et al. 2023 identified a second mechanism specific to Lion's Mane mycelium polysaccharide: increased SCFA production that activates GPR41/43 receptors on the colon wall, operating separately from the NF-κB pathway
- Short-term consumption by healthy volunteers showed no adverse effects (Szydłowska 2021); no safety data exists for IBD patients specifically
The Honest Starting Point: Lion's Mane Has Never Been Tested in a Human IBD Clinical Trial
Lion's Mane (Hericium erinaceus) has not been tested in an IBD clinical trial. That single sentence distinguishes this article from most consumer content on the topic, and it is the necessary starting point.
Inflammatory bowel disease comes in two main forms. Crohn's disease causes inflammation that can penetrate the full thickness of the gut wall and affect any part of the gastrointestinal tract, most commonly the small intestine. Ulcerative colitis causes inflammation confined to the inner lining of the colon. Both are autoimmune conditions, driven by the immune system attacking the gut rather than by a chemical irritant or pathogen. This is not IBS (irritable bowel syndrome), which is a functional gut disorder with different mechanisms and a different evidence base. The distinction matters because compounds that work in IBD models are not automatically useful for IBS, and vice versa.
When researchers evaluate a compound for IBD, the gold standard is a randomized controlled trial (RCT) in patients with confirmed Crohn's or ulcerative colitis. One mushroom species has cleared that bar: Agaricus blazei, tested by Therkelsen and colleagues in a 2016 Crohn's disease RCT that showed reduced disease activity, fatigue, and quality-of-life deficits in 46 patients. Agaricus blazei is not Lion's Mane.
The Lion's Mane evidence for IBD falls into three categories: animal colitis studies (most of the data), one ex vivo study using actual human IBD biopsy tissue, and one short-term human safety study in healthy (non-IBD) volunteers. Being explicit about which category each finding belongs to is the foundation for reading this research honestly.
For a direct comparison of human evidence across all mushroom species studied in IBD, see Mushrooms for IBD: Can They Help Crohn's and Ulcerative Colitis?.
The 2023 Pivot: Researchers Finally Used Actual IBD Patient Tissue
Gravina and colleagues published an ex vivo study in Frontiers in Immunology testing a nutraceutical formulation containing H. erinaceus alongside berberine (a plant alkaloid), quercetin (a flavonoid), and vitamins B3 and B8.[7] Tissue samples were collected by endoscopy from patients with active IBD, preserving the cellular environment of inflamed intestinal mucosa. Ex vivo means the researchers took living tissue out of the body and tested the compound on it in a lab dish. The tissue came directly from the disease being studied.
The results: the combination produced a progressive decrease in COX-2 and TNF-α at both the gene expression and protein levels, while IL-10 increased. Three terms worth unpacking.
COX-2 is the enzyme that manufactures the local hormones (prostaglandins) that amplify inflammation in damaged tissue. Ibuprofen and other NSAIDs work by blocking COX-2. In IBD, COX-2 is chronically overactive in inflamed gut tissue.
TNF-α (tumor necrosis factor alpha) is one of the primary inflammatory signaling proteins in Crohn's disease and ulcerative colitis. It is the exact target of the most widely used biologic drugs in IBD treatment: infliximab and adalimumab, which are expensive monoclonal antibodies that bind and neutralize TNF-α. Seeing TNF-α decrease in actual IBD patient tissue is pharmacologically meaningful, not incidental.
IL-10 is the gut's principal anti-inflammatory signal. In active IBD flares, IL-10 production is suppressed while pro-inflammatory cytokines dominate. Restoring IL-10 is a recognized therapeutic goal in IBD management.
Three caveats apply. The formula was a combination product: the anti-inflammatory effects cannot be attributed to Lion's Mane alone. Ex vivo tissue responses in a dish do not guarantee the same effects would occur in living patients taking the formula orally, where absorption, intestinal transit, and systemic pharmacology all intervene. And the study measured biological markers in tissue, not clinical outcomes like disease remission or symptom scores in actual patients.
The Abdualrahman 2023 review of Lion's Mane across GI and neurological conditions places this ex vivo data as the most clinically proximate evidence in the Lion's Mane IBD literature, while clearly framing it within a mostly preclinical evidence base.[6]
Three Mechanisms Mapped in Animal Colitis Studies
Animal colitis studies have identified three distinct pathways through which Lion's Mane may reduce gut inflammation. Each has been characterized in independent experiments using different fractions of the mushroom. Together they describe a mechanistically coherent picture even without human trial data.
Mechanism 1: Blocking the Central Inflammation Switch
NF-κB (nuclear factor kappa B) is a protein complex that acts as the master switch for gut inflammation. In IBD, it gets stuck in the activated state inside gut immune cells, continuously driving production of inflammatory proteins. Several standard IBD drugs, including corticosteroids, work partly by suppressing NF-κB.
Qin and colleagues tested Lion's Mane ethanol extract at 250 mg/kg and 500 mg/kg in mice with DSS-induced colitis.[2] Treated mice showed less intestinal bleeding, longer colon length (a marker of reduced colitis severity, since inflamed colons shorten), and suppressed levels of TNF-α, IL-1β, and IL-6. Three of the primary inflammatory proteins in IBD, all reduced via NF-κB inhibition.
Ren and colleagues confirmed the NF-κB pathway and mapped two additional targets in the same experiment: phosphorylation of the MAPK pathway (another inflammation regulator) and the Akt pathway (a cell survival signal that is overactivated in IBD mucosa).[4] Three signaling pathways simultaneously reduced by one compound is an unusually comprehensive mechanistic profile for a food-derived polysaccharide. Ren's study also documented reduced oxidative stress: the antioxidant enzyme superoxide dismutase (SOD) increased, and malondialdehyde (a marker of oxidative damage to cell membranes) decreased.
Mechanism 2: Reshaping the Gut Microbial Community
IBD is closely tied to gut dysbiosis, an imbalance in the microbial community characterized by reduced Ruminococcaceae (bacteria that produce butyrate) and increased Proteobacteria (a group that includes many opportunistic pathogens). Restoring that balance is a recognized therapeutic target in IBD.
Diling and colleagues found that H. erinaceus polysaccharide and protein fractions specifically increased Bifidobacterium populations in colitis mice while reducing Proteobacteria.[3] The team proposed that Lion's Mane acts through a combined immune regulation and microbiome mechanism: the two effects reinforce each other rather than operating independently. Ren 2018 corroborated this, showing increases in Ruminococcaceae specifically, the group most important for butyrate production.[4]
For a broader discussion of how mushroom polysaccharides alter gut microbial composition across species, see How Mushrooms Change Your Gut Microbiome: Research Review. For the most studied mushroom species specifically for gut microbiota effects in a human trial, see Turkey Tail and Gut Bacteria: The Most-Studied Prebiotic Mushroom.
Mechanism 3: Producing Anti-Inflammatory Signals Through Gut Bacteria
Short-chain fatty acids (SCFAs), particularly butyrate, are produced when gut bacteria ferment polysaccharides. Butyrate is the primary energy source for colonocytes, the cells lining the colon. It also signals through two receptor proteins on the colon wall, GPR41 and GPR43, triggering anti-inflammatory effects. In IBD, SCFA production is typically reduced because the butyrate-producing bacteria have been depleted by dysbiosis.
Pan and colleagues found that Lion's Mane mycelium-derived polysaccharide in a UC mouse model increased SCFA production and specifically activated GPR41 and GPR43 receptor signaling.[8] This pathway is mechanistically distinct from NF-κB inhibition: it operates through the microbiome rather than by directly blocking the inflammatory switch in gut immune cells. Both mechanisms may operate at the same time through different routes.
The combined picture from Ren 2018 and Pan 2023 is coherent: Lion's Mane polysaccharides restore the microbial community that produces butyrate, and butyrate then signals the colon wall to reduce inflammation. Animal data, not human data. But three independent pathways documented by independent research groups.
The Gastroprotective Origin: Why Stomach Ulcer Research Matters Here
The Lion's Mane IBD research did not begin with Crohn's disease or colitis. It began with gastric ulcers.
Wong and colleagues showed in 2013 that H. erinaceus aqueous extract significantly reduced ulcer area in rats with ethanol-induced gastric ulcers.[1] The mechanism they mapped was specific to mucosal protection. The extract upregulated HSP70, a heat shock protein that acts as a cellular stress buffer, helping gut lining cells survive damage without dying. At the same time it downregulated BAX, a protein that triggers programmed cell death (apoptosis) in damaged cells. It also prevented depletion of the gut lining's antioxidant enzymes.
The plain-language version: Lion's Mane made the stomach's protective cells harder to kill and less likely to self-destruct when under chemical stress.
This gastroprotective mechanism is not the same as the IBD anti-inflammatory mechanism. Ethanol-induced gastric ulcers are a local chemical injury, not an autoimmune disease. The sustained immune dysregulation in Crohn's and UC is fundamentally different from acute chemical damage. But the tissue-level relevance to IBD is real: in both conditions, mucosal cells are dying faster than they are being replaced, and the intestinal barrier is losing integrity. The HSP70/BAX pathway that Wong 2013 identified in the stomach operates in the intestinal mucosa as well.
The Abdualrahman 2023 review positions this gastroprotective data as the foundational rationale for Lion's Mane's gut activity, which the subsequent colitis research expanded mechanistically.[6] The stomach and colon are anatomically distant, but the cellular protection machinery overlaps more than that distance suggests.
Mycelium vs. Fruiting Body: Why the Form May Matter for IBD Research
Most Lion's Mane colitis research does not specify whether mycelium or fruiting body was used. The Pan 2023 study is an exception: it tested mycelium-derived polysaccharide and traced the SCFA-GPR41/43 pathway specifically to that fraction.[8]
This matters because many Lion's Mane supplements use mycelium grown on grain substrates. Researchers have raised concerns that some mycelium products contain significant starch from the growing medium rather than pure mushroom polysaccharides. The Pan 2023 finding establishes that mycelium-derived polysaccharide has IBD-relevant biological activity in mice, but it cannot tell us whether a commercial mycelium product with variable polysaccharide content would replicate that result.
The earlier colitis studies (Wong 2013, Qin 2016, Diling 2017, Ren 2018) used aqueous or ethanol extracts without specifying the mushroom part. Their NF-κB, microbiota, and oxidative stress findings represent the broader pool of Lion's Mane compounds without distinguishing the contribution of mycelium versus fruiting body. No study has directly compared the two forms for IBD-relevant outcomes.
The practical implication is a research gap, not a recommendation about product form. Polysaccharide-dependent anti-colitis activity appears present in both mycelium and fruiting body preparations, but the research does not currently support confident claims about which form is more effective for gut inflammation. For more on how mushroom beta-glucan structures interact with gut immune receptors, see Mushroom Beta-Glucans and Gut Inflammation: IBD Research.
Human Safety Data Exists, But Only for Healthy Volunteers
The most direct human evidence comes from Szydłowska and colleagues, who tracked biochemical markers in healthy volunteers consuming H. erinaceus short-term and found no adverse effects.[5] Biochemical shifts were consistent with hepatoprotective and anti-inflammatory activity. The finding establishes a basic safety floor in healthy adults.
IBD patients are a different population. They are commonly treated with immunosuppressants (azathioprine, 6-mercaptopurine), biologics targeting TNF-α or gut-specific integrin receptors (vedolizumab), or corticosteroids. Lion's Mane modulates several of the same inflammatory pathways that these drugs affect. Whether combining Lion's Mane with these treatments produces additive, neutral, or countervailing effects has not been studied, because no study has enrolled IBD patients on standard medical therapy.
On dosing: animal studies used weight-based doses (250 to 500 mg/kg in Qin 2016) that cannot be translated directly to human doses. No study has established what dose of Lion's Mane in what form over what duration would produce measurable effects in IBD patients. Consumer products commonly offer 500 to 1000 mg per dose, but this range has not been evaluated in any IBD context.
For the full picture of mushroom species studied in IBD, including Agaricus blazei with its human RCT data, see Anti-Inflammatory Mushrooms for Inflammatory Bowel Disease.
The Bottom Line
Lion's Mane (Hericium erinaceus) has a coherent research profile for IBD built across animal colitis studies documenting three distinct anti-inflammatory mechanisms and a 2023 ex vivo study using actual IBD patient tissue. What it does not have is a human randomized controlled trial. The animal evidence is consistent across independent research groups and covers NF-κB inhibition, gut microbiota restoration, and SCFA-mediated receptor signaling. The Gravina 2023 ex vivo data is the closest the literature has come to human clinical evidence. The gap between that and a proven benefit for IBD patients is real and has not been closed.
Frequently Asked Questions
Sources & References
- 1RTHM-00564·Wong, Jing-Yang et al. (2013). “Gastroprotective Effects of Lion's Mane Mushroom Hericium erinaceus (Bull.:Fr.) Pers. (Aphyllophoromycetideae) Extract against Ethanol-Induced Ulcer in Rats..” Evidence-based complementary and alternative medicine : eCAM.Study breakdown →PubMed →↩
- 2RTHM-00442·Qin, Mingming et al. (2016). “Anti-Inflammatory Effects of Ethanol Extract of Lion's Mane Medicinal Mushroom, Hericium erinaceus (Agaricomycetes), in Mice with Ulcerative Colitis..” International journal of medicinal mushrooms.Study breakdown →PubMed →↩
- 3RTHM-00470·Diling, Chen et al. (2017). “Extracts from Hericium erinaceus relieve inflammatory bowel disease by regulating immunity and gut microbiota..” Oncotarget.Study breakdown →PubMed →↩
- 4RTHM-00529·Ren, Yilin et al. (2018). “Polysaccharide of Hericium erinaceus attenuates colitis in C57BL/6 mice via regulation of oxidative stress, inflammation-related signaling pathways and modulating the composition of the gut microbiota..” The Journal of nutritional biochemistry.Study breakdown →PubMed →↩
- 5. Source details for this reference are not yet available.
- 6. Source details for this reference are not yet available.
- 7RTHM-01701·Gravina, Antonietta Gerarda et al. (2023). “Hericium erinaceus, in combination with natural flavonoid/alkaloid and B3/B8 vitamins, can improve inflammatory burden in Inflammatory bowel diseases tissue: an ex vivo study..” Frontiers in immunology.Study breakdown →PubMed →↩
- 8. Source details for this reference are not yet available.